← Metformin × cardiovascular events

Observational studyCardiovascular diabetology2018

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.

Cheng-Wei Chan et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 26,742 people · 2018

Randomised comparison

Reduced cardiovascular events

−34%−50% to −12%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.66, 95% CI 0.50–0.88

Randomised comparison

Reduced cardiovascular events

−26%−41% to −6%

Bigger than 6 in 10 for cardiovascular events

As reported

HR 0.74, 95% CI 0.59–0.94

Two numbers in the abstract

the abstract, start to end

… the TZD+metformin (adjusted HR: 0.66; 95% CI 0.50-0.88, p = 0.004) and AGI+metformin (adjusted HR: 0.74; 95% CI 0.59-0.94, p = 0.01) …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.660.50–0.88
Cardiovascular events
HR 0.740.59–0.94
MetforminThiazolidinedionesCardiovascular events
1 / 3

28 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 29368615